Supply of Medicines and Medicinal Products II

Summary

The tender concerns the supply of medicines and medicinal products to the hospital pharmacy of the National Cancer Institute in Bratislava for 24 months. It is divided into eight lots: carmustine with propylene glycol, carmustine with anhydrous ethanol, cytostatics, cabazitaxel, sacituzumab govitecan, avelumab, nivolumab and ipilimumab, and trastuzumab deruxtecan. Delivery includes transport to the destination, unloading and packaging disposal. The estimated total value is EUR 22,381,560.30. Tenderers may bid for up to eight lots and may be awarded up to eight lots. The lowest price is the sole award criterion for each lot, and an electronic auction will be used. A tender guarantee is mandatory and must be provided by the submission deadline; its amount and detailed terms must be checked in the tender documents. Bids must be submitted electronically by 11 November 2026 at 10:00. The precise qualification and other participation requirements are set out in the tender documents.